Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?
作者信息
Roh Ji Woong, Kim Yongcheol
机构信息
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, Korea.
出版信息
Korean Circ J. 2022 Jul;52(7):556-557. doi: 10.4070/kcj.2022.0105. Epub 2022 May 16.
Abstract
摘要
相似文献
1
Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?
Korean Circ J. 2022 Jul;52(7):556-557. doi: 10.4070/kcj.2022.0105. Epub 2022 May 16.
2
Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results.
J Cardiovasc Med (Hagerstown). 2018 Jul;19(7):337-343. doi: 10.2459/JCM.0000000000000662.
3
Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention.
ESC Heart Fail. 2022 Feb;9(1):545-554. doi: 10.1002/ehf2.13715. Epub 2021 Nov 22.
4
Beta blockers versus calcium channel blockers for provocation of vasospastic angina after drug-eluting stent implantation: a multicentre prospective randomised trial.
Open Heart. 2020 Oct;7(2). doi: 10.1136/openhrt-2020-001406.
5
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.
Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
6
Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials.
Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):469-477. doi: 10.1177/2048872619830609. Epub 2019 Feb 14.
7
Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift?
Recent Pat Cardiovasc Drug Discov. 2014;9(1):11-21. doi: 10.2174/1574890109666140901144210.
8
Prognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention.
Pharmacol Res. 2021 Jul;169:105614. doi: 10.1016/j.phrs.2021.105614. Epub 2021 Apr 16.
9
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.
Vasc Health Risk Manag. 2010 Sep 7;6:749-74. doi: 10.2147/vhrm.s11100.
10
Chronic Kidney Disease and Post-Percutaneous Coronary Intervention Mortality in Patients With Left Main and Equivalent Coronary Artery Disease.
Tex Heart Inst J. 2022 Sep 1;49(5). doi: 10.14503/THIJ-21-7670.
本文引用的文献
1
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.
Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
2
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.
Korean Circ J. 2022 Mar;52(3):173-197. doi: 10.4070/kcj.2021.0401.
3
Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database.
Korean Circ J. 2020 Jun;50(6):499-508. doi: 10.4070/kcj.2019.0231. Epub 2020 Jan 6.
4
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425.
5
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
6
Expert consensus document: A 'diamond' approach to personalized treatment of angina.
Nat Rev Cardiol. 2018 Feb;15(2):120-132. doi: 10.1038/nrcardio.2017.131. Epub 2017 Sep 7.
7
β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.
BMJ. 2016 Sep 20;354:i4801. doi: 10.1136/bmj.i4801.
8
Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
JACC Cardiovasc Interv. 2016 Aug 22;9(16):1639-48. doi: 10.1016/j.jcin.2016.05.048.
9
β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
Int J Cardiol. 2013 Sep 30;168(2):774-9. doi: 10.1016/j.ijcard.2012.10.001. Epub 2012 Nov 2.
10
Effect of carvedilol on survival in severe chronic heart failure.
N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201.
Zotero 插件